Dr Claudio Cerchione talks to ecancer at EHA 2024 about his abstract.

The PREAMBLE registry study evaluated real-world outcomes for multiple myeloma patients previously treated with lenalidomide.

The study found that progression-free survival decreased with each subsequent treatment post-lenalidomide, dropping from 13.9 months on lenalidomide to 4.5 months by the fifth treatment.

Despite a consistent overall response rate of around 30.9% for post-lenalidomide treatments, most patients experienced disease progression.

This indicates a significant need for more effective treatments for patients after lenalidomide exposure.